Originally published November 3, 2009 at 8:51 AM | Page modified November 3, 2009 at 9:26 AM

Comments (0) E-mail article Print view Share

Merck to complete $41B purchase of Schering-Plough

Merck & Co. is set to complete its $41 billion acquisition of Schering-Plough Corp. later Tuesday, creating the world's second-largest drugmaker, behind Pfizer Inc.

The Associated Press

FDA won't accept Merck's application for new drug

WHITEHOUSE STATION, N.J. —

Merck & Co. is set to complete its $41 billion acquisition of Schering-Plough Corp. later Tuesday, creating the world's second-largest drugmaker, behind Pfizer Inc.

The companies expect the deal will close after the end of market trading Tuesday.

The completion comes after the U.S. Federal Trade Commission approved the deal Thursday. Regulators in Europe and elsewhere, and shareholders of both companies, have already approved it.

The two companies have been jointly selling the cholesterol drugs Vytorin and Zetia for years.

The deal adds allergy drugs Nasonex and Clarinex to Merck's Singulair and its diabetes pill Januvia. It also gives Merck animal and consumer health products, and a promising biotech division.

(CORRECTS to say deal will close later Tuesday.)

E-mail article Print view Share

More Business & Technology

Nintendo re-enlists Mario, savior of video-game industry

Verizon-Frontier deal stirs concern among consumers

Brier Dudley: 'Guitar Hero' founder excited about future

Gaps for consumers in Democrat health care bills

Hutch gets $10M from Bezos family for immunotherapy research

More Business & Technology headlines...

Comments (0)

Hide comments / Show comments

No comments have been posted to this article. Start the conversation.